Reviewing Curis Inc. (CRIS)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

This is therefore a contrasting of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Curis Inc. (NASDAQ:CRIS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 demonstrates Curis Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Curis Inc. and Brainstorm Cell Therapeutics Inc.s return on assets, return on equity and net margins.

Risk and Volatility

A 2.47 beta means Curis Inc.s volatility is 147.00% more than Standard and Poors 500s volatility. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard and Poors 500.

Liquidity

The Current Ratio and a Quick Ratio of Curis Inc. are 9.8 and 9.8. Competitively, Brainstorm Cell Therapeutics Inc. has 1 and 1 for Current and Quick Ratio. Curis Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 24.7% of Curis Inc. shares and 11.4% of Brainstorm Cell Therapeutics Inc. shares. 17.28% are Curis Inc.s share held by insiders. Insiders Comparatively, held 0.6% of Brainstorm Cell Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Curis Inc. was more bullish than Brainstorm Cell Therapeutics Inc.

Summary

Curis Inc. beats on 7 of the 9 factors Brainstorm Cell Therapeutics Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original here:
Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly